NEWS & PRESS

Syndivia Syndivia

Publication in Bioconjugate Chemistry

Syndivia introduces a first-in-class reagent for kinetically resolved thiol-to-thiol conjugation in its recent publication in Bioconjugate Chemistry. The MAPN reagent allows for the preparation of stable Antibody-Drug Conjugates through conjugation of thiol-containing drugs to the cysteine residues of the antibody.
The publication can be downloaded on the ACS website: http://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.5b00440

1970467.png
Read More
Syndivia Syndivia

Syndivia lands €275k grant to develop next-generation targeted cancer therapies

Syndivia was nominated laureate of the i-LAB 2015 in the category "création-développement". i-LAB is a nationwide contest of innovative companies supported by the French Ministry of Higher Education and Research. The prize includes €275k financial support for Syndivia's R&D program on the development of next-generation targeted cancer therapies.

9838246.png
Read More
Syndivia Syndivia

Syndivia is among the TOP 100 SMEs of the Hello Tomorrow Challenge

Syndivia is selected as one of the TOP100 startups of the Hello Tomorrow Challenge, placing it in the top 3% of the projects participating in the contest.

Hello Tomorrow Challenge is a global competition of tech-startups with more than 3600 participants spread across 6 major tech fields: Energy & Environment, Information Technologies, Food & Agriculture, Healthcare, Materials & Manufacturing, and Transport & Mobility.

4925767.png
Read More
Syndivia Syndivia

Syndivia is granted the prestigious MATWIN label

Following the final presentation in front of the International Board of MATWIN, the project ADC 2.0, presented by Syndivia, was granted the MATWIN label and the prize in the category of "Best Challenging Project". The prestigious MATWIN label rewards high-quality projects with strong potential in the area of oncology.
MATWIN (Maturation & Accelerating Translation With INdustry) is a nationwide service platform which is unique in Europe and which supports the maturation of research projects in oncology, up to the pre-clinical proof of concept.

3854579.jpg
Read More